DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.
Medicines that matter
Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.
DURECT has now staked out important positions in areas as diverse as pain management, psychiatry, metabolic disease, and acute organ injury. As we pursue our goals, we continue to ask ourselves the following questions: Are the therapies we propose to bring to market products of which we can truly be proud? Are they worthy of the formidable effort required to advance them through the FDA and international approval processes? Will they have a meaningful impact on the outcome that ultimately matters most—the well-being of the individuals treated with them?
- Advance medicine by adhering strictly to strong science
- Strive to have multiple approved products on the market
- Make a difference in the real world
- Be a good clinical and commercial partner
- Provide an environment where talented, dedicated people can deliver their best
- Be ethical and honest
- Aim high and persevere through challenges